Sera Prognostics, Inc.
HealthcareNASDAQ:SERA · NASDAQ Global Market
-$0.06 today
Vol 0.05M · Avg 0.07M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-42.3%
avg -151.2%
ROIC
-47.0%
avg -68.7%
ROA
-31.3%
avg -54.5%
Analysis
ROA is currently the strongest return metric at -31.3% versus its period average of -54.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Zhenya Lindgardt | President, Chief Executive Officer & Director | $1.01M | — | 52 | $871,999.00 | 2.28% |
John J. Boniface | Chief Scientific Officer | $619,780.00 | — | 64 | $0.00 | <0.01% |
Paul Kearney | Chief Data Officer | $600,279.00 | — | 58 | $0.00 | <0.01% |
Tiffany Inglis FACOG | Chief Medical Officer | $575,549.00 | — | — | $27,034.00 | 0.07% |
Benjamin G. Jackson | General Counsel & Corporate Secretary | $410,755.00 | — | 47 | $163,935.00 | 0.43% |
Robert G. Harrison | Chief Information Officer | $384,178.00 | — | 60 | $0.00 | <0.01% |
Austin Aerts | Chief Financial Officer | $367,625.00 | — | 39 | $303,227.00 | 0.79% |
Gregory C. Critchfield | Executive Director | $35,000.00 | — | 73 | $822,866.00 | 2.15% |
Chuck Hyde | Head of Market Access | — | — | — | — | — |
Lee Anderson | Chief Commercial Officer | — | — | — | $82,737.00 | 0.22% |
Jennifer Zibuda | Head of Investor Relations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
66
$845,704.79
Net Sentiment
$845,704.79
Net selling
Most Active
Harrison Robert Gardner
14 transactions
1–10 of 66
Analysis
Insiders reported 0 buys worth $0.00 and 66 sells worth $845,704.79 over the last 12 months. That adds up to net selling of $845,704.79. Harrison Robert Gardner was the most active insider with 14 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +130.5% | +97.4% (7yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +130.5% over three years. Forward estimates point to Revenue at +97.4% (7yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Apyx Medical Corporation
NASDAQ:APYX
$196.39M
Surrozen, Inc.
NASDAQ:SRZN
$174.90M
TuHURA Biosciences, Inc.
NASDAQ:HURA
$147.74M
Lucid Diagnostics Inc.
NASDAQ:LUCD
$98.28M
Cognition Therapeutics, Inc.
NASDAQ:CGTX
$89.03M
Oncolytics Biotech Inc.
NASDAQ:ONCY
$80.59M
Rapid Micro Biosystems, Inc.
NASDAQ:RPID
$79.77M
SkyAI, Inc.
STSS
$47.61M
Tevogen Bio Holdings Inc.
TVGN
$43.84M
Atossa Therapeutics, Inc.
ATOS
$21.18M
Who manages SERA?
Sera Prognostics, Inc. (SERA) lists 11 active executives. The top listed executive is Austin Aerts, Chief Financial Officer.
Are SERA insiders buying or selling?
Recent insider activity shows net buying of $1.29M.
Explore More
Continue the stock analysis
Jump to another research area for this company.